Spectrum Pharmaceutecals Inc (SPPI)

[antihama]

Pfizer’s EGFR TKI lung cancer candidate, dacomitinib was in the news at ASCO. It met its phase 3 primary endpoint in NSCLC. It failed 2 previous P3 trials in NSCLC back in 2014 so what changed? In this trial it zeroed in on EGFR-activating mutations. So will this be competition for Poziotinib in patients with EGFR Exon 20 Insertion? Nah! A look at the trial details shows that the exclusion criteria includes patients with

Any other mutation other than exon 19 deletion or L858R in exon 21, with or without the presence of the exon 20 T790M mutation.

Last I checked, EGFR Exon 20 Insertion would be “Any other mutation”.

http://www.asco.org/about-asco/press-center/news-releases/research-suggests-possible-new-treatment-egfr-positive-lung